Value through InnovationOctober 27 2016

Medical Education Grants

Boehringer Ingelheim is proud to provide Medical Education Grant support for specific independent educational activities for healthcare providers and patients that may translate to better management of disease and improvement in patient safety and population health. An independent educational program may be at the national, regional or local level and may include but is not limited to, live and interactive didactic presentations (e.g., symposia at major educational meetings, grand rounds, regional workshops), web-based programs, print and electronic monographs and other innovative educational formats.

The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI.  To contact Boehringer Ingelheim Pharmaceuticals, Inc. Medical Education Grants Department, please send an email to To explore an online tutorial about the Medical Education Grants application process, click here.


Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) has implemented new business practices to satisfy the government reporting requirements under the Physician Payments Sunshine Act, which was part of the 2010 Patient Protection and Affordable Care Act.

The Final Rule regarding transparency reporting was released by CMS on February 1, 2013  and requires applicable manufacturers (e.g., BIPI) to collect and annually report payments and other transfers of value provided to  U.S.-licensed practitioners (i.e., MDs/DOs, chiropractors, dentists, podiatrists and chiropractors) and certain Teaching Hospitals (“Covered Recipients”). BIPI provides both direct and indirect transfers of value to Covered Recipients through medical education grants.

Beginning January 1, 2016 CMS has removed the CME exclusion from Open Payments reporting.  The exclusion allowed applicable manufacturers (AM) to exclude reporting payments or transfers of value to faculty of accredited CME programs.  The result of this change is that, starting in 2016, when an applicable manufacturer provides an indirect payment or other transfer of value to a continuing education organization for a continuing education event to physicians, and knows or finds out the identity of the physician attendees/speakers within the reporting year or by the end of the second quarter of the following reporting year, that payment must be reported to CMS within 30 days of the transfer of value.

Due to this change, Boehringer Ingelheim Pharmaceuticals, Inc. will begin to report data on transfers of value for all covered recipients regardless of program accreditation after January 1, 2016. To provide greater clarity surrounding BIPI’s reporting requirements as it pertains to the” Physician Payments Sunshine Act” under medical education grants, please refer to the document “Medical Education Grants Sunshine Reporting Requirements”.

This document will describe the grant recipient’s (educational provider’s) responsibilities to report to BIPI certain indirect payments to Covered Recipients.  The document addresses those scenarios considered relevant by BIPI for reporting which are inclusive of speaker and attendee payment reporting for: (1) accredited HCP education, (2) non-accredited HCP education, and (3) non-accredited patient and community medical education.

For more information, please contact the Medical Education and Research Grants Office @

Boehringer Ingelheim Pharmaceuticals, Inc. considers funding of activities both independently and through its alliance arrangement with Lilly USA, Inc. in a variety of areas including:

BIPI Areas of Strategic Focus

Cardiovascular Disease (Limited Funding Available)

Stroke Prevention in Atrial Fibrillation Educational Objectives

  1. Highlight the under-recognized risk of cardioembolic stroke in untreated and under-treated NVAF patients and the disease-associated morbidity, mortality, and cost burdens.
  2. Effectively assess the risk/benefit ratio of cardioembolic stroke prophylaxis for the NVAF patient.
  3. Enable clinicians to make informed treatment recommendations for cardioembolic stroke risk reduction in individual NVAF patients based upon current guidelines, patient co-morbidities, lifestyle, and social factors.
  4. Discuss current and potential new challenges and opportunities in cardioembolic stroke prevention in NVAF with oral anticoagulants.
  5. Support strategies to enhance communication between clinicians and their NVAF patients /caregivers about the stroke risk reduction benefits and bleeding risks of anticoagulation therapy, and the importance of persistence with therapy.
  6. Increase  healthcare providers’ knowledge of the management of bleeding in patients on oral anticoagulants. or patients at risk of bleeding who are taking oral anticoagulants.

Venous Thromboembolism (VTE) Educational Objectives

  1. Enhance awareness of the challenges of diagnosing patients with venous thromboembolic events using available diagnostic tools, including appropriate laboratory assessments.
  2. Optimize and align treatment guidelines and algorithms for VTE management and incorporate these into clinical practice to improve patient outcomes.
  3. Using an evidence- based approach enhance knowledge and awareness of VTE management options with conventional agents and NOACs in evaluating patient outcomes, including clot resolution and bleeding risk.
  4. Enhance knowledge of the scientific evidence that weighs patient risk factors with the optimal treatment duration.
  5. Improve communication amongst HCPs and between HCPs and their patients/caregivers about the importance of compliance, adherence, and persistence in anticoagulant therapy, especially in the setting of transitions from inpatient to community-based care.
  6. Increase healthcare providers’ knowledge of the management of bleeding in patients on oral anticoagulants. or patients at risk of bleeding who are taking oral anticoagulants.

Diversity of Investigative Staff and Patient Populations in Clinical Trials (Funding Not Available)

Diversity of Investigative Staff and Patient Populations in Clinical Trials Educational Objectives

  1. Improve knowledge regarding disease specific standards of care and regulatory requirements for demonstrating safety and efficacy of treatments in diverse patient populations
  2. Develop awareness regarding barriers and support the understanding of strategies to improve basic clinical research competencies  among minority-serving  health care providers.
    a. Improve understanding around cultural and structural competencies that enable clinical trial completion
  3. Foster an understanding  of both healthcare provider and patient biases about clinical trial participation.
  4. Understand barriers to reliable clinical trial recruitment and retention among experienced minority-serving investigators.
  5. Develop effective communication strategies between  interdisciplinary healthcare providers and patients to  effectively, identify, engage and retain diverse populations in clinical trials.


Non-Small Cell Lung Cancer (NSCLC) Educational Objectives (Limited Funding Available)

  1. Increase clinicians’ understanding of the heterogeneity of disease among patients with NSCLC and the clinical impact of distinguishing between subpopulations (e.g. different histologies, different sub-types) to optimize therapeutic strategies.
  2. Increase clinicians’ knowledge and appropriate application of evidence-based clinical data for the management of solid tumors (including NSCLC).
  3. Review the management of adverse events associated with the use of oral anti-EGFR agents.

Head and Neck Cancers Educational Objectives (Funding Not Available)

  1. Improve early detection and early intervention efforts for patients with HNSCC.
  2. Expand understanding of tumor biology, prognosis, and current therapeutic options for patients with HNSCC.
  3. Increase understanding of ongoing clinical research for the treatment of patients with HNSCC.
  4. Increase clinicians’ knowledge and appropriate application of evidence-based clinical data in selection of therapeutic options for the management of solid tumors (including HNSCC).
    • Understand how safety and tolerability of treatment may impact patient outcomes


Chronic Obstructive Pulmonary Disease (COPD) Educational Objectives (Limited Funding Available)

  1. Diagnosis of COPD: Address mis-diagnosis and under-diagnosis of COPD, especially among primary care physicians, by improving HCPs’ ability to correctly identify patients at risk for COPD earlier, understand asthma-COPD overlap syndrome (ACOS), and the role of spirometry.
  2. Management of COPD:  Improve COPD management through improving HCP knowledge and application of COPD guidelines, approaches to and benefits of both non-pharmacologic disease management  and pharmacologic treatment with emphasis on proper incorporation of ICS and the appropriate role of long acting bronchodilators in COPD, the spectrum and approaches to disease management, and the prevalence and spectrum of comorbidities.
  3. Management of Exacerbations: Educate all HCPs on  recognition and associated clinical impact  of COPD exacerbations, relevant management strategies, and avoidance of risk factors that can trigger an exacerbation
  4. Coordination of Care and Transitionary Care: Increase education and approaches on coordination of care among the multi-disciplinary team to ensure optimal transition of care for the COPD patient and reduce COPD readmissions.
  5. COPD Pathophysiology: Increase the understanding of COPD pathophysiology, including the cholinergic, sympathomimetic, and inflammatory components, and the rationale for use of therapeutic agents with different mechanisms of action.
  6. Patient Education: Improve patient awareness and knowledge of COPD diagnosis, proper use of different inhalers to improve compliance to treatment regimens, including self-management strategies (written action plans).

Interstitial Lung Disease (ILD) Educational Objectives

  1. Disease course, diagnosis and assessment: Increase clinicians’ understanding of disease prevalence, morbidity and mortality, and signs and symptoms of ILD (IPF, Connective Tissue Disease (CTD) related ILD). Additionally improve clinician’s knowledge of recommended diagnostic testing methods and interpretation (e.g. HRCT surgical biopsy, serologic testing) and the importance of routine, comprehensive multidisciplinary assessments in patients with CTD-ILD.
  2. Earlier identification and differentiation of ILDs:  raise the index of awareness of ILD among HCPs to encourage earlier referral of appropriate patients with ILD (IPF and Connective Tissue Disease related ILD) to ILD centers.
  3. Treatment guidelines and clinical management: Improve clinicians’ knowledge regarding IPF clinical management, including their familiarity with and awareness of changes in available treatment guidelines and developments in clinical research.
  4. ILD clinical trial endpoints: Educate clinicians on data from randomized controlled trials (RCTs) to ensure that therapeutic decision-making is based on the latest scientific evidence.
  5. IPF risk factors and co-morbidities: Increase understanding among pulmonologists regarding management of the possible IPF risk factors and co-morbidities for IPF (such as GERD), as well as the importance of managing other co-morbidities.
  6. HCP communication with patients: Improve clinicians understanding of how to communicate with ILD patients and their ability to effectively educate ILD patients about their disease.


To view Therapeutic Areas of interest and begin the process of applying for a Medical Education grant within supported by the Boehringer Ingelheim Pharmaceutical Inc (BIPI) and Eli Lilly and Company (Lilly) global Alliance agreement, click here.

Funding may be limited or exhausted in some therapeutic areas. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes. To review these objectives, please click on the therapeutic area of interest above. Boehringer Ingelheim Pharmaceuticals, Inc. considers support for the following grant types:

  • Accredited independent educational programs for healthcare providers, e.g. Grand Rounds and Independent Medical Education
  • Non-accredited independent educational programs directed toward the patient and healthcare community, e.g. patient educational materials and scientific meetings.

Applying for a Medical Grant

Medical Education Grants

Learn more about applying for a medical grant for an educational activity.

Medical Grants Brochure

Learn more about types of program support.

Medical Education Grants Tutorial

Explore a self-paced tutorial before beginning the grant application process